. Author manuscript; available in PMC: 2017 Sep 27.

Published in final edited form as: Lancet Infect Dis. 2015 Dec 23;16(3):331–338. doi: 10.1016/S1473-3099(15)00489-2

Table 3.

Features of acute Ebola virus disease illness associated with convalescent symptoms and diagnoses at first survivor clinic visit.

	Uveitis			Ocular symptom or ocular diagnoses¹			Auditory symptoms²			Arthralgias²
	Yes (N=50)	No (N=227)	p	Yes (N=167 )	No (N=110 )	p	Yes (N=67 )	No (N=210 )	p	Yes (N=210 )	No (N=67 )	p
Sex			0·08			0·08			0·08			0·90
Female	35(70%)	128 (56%)		105 (63%)	58 (53%)		40 (60%)	123 (59%)		124 (59%)	39 (58%)
Male	15 (30%)	99 (44%)		62 (37%)	52 (47%)		27 (40%)	87 (41%)		86 (41%)	28 (42%)
Age-group (years)			0·34³			0·31³			0·18³			0·004³
< 5	0 (0%)	6 (3%)		3 (2%)	3 (3%)		0 (0%)	6 (3%)		3 (1%)	3 (4%)
5–20	10 (20%)	54 (24%)		33 (20%)	31 (28%)		15 (22%)	49 (23%)		40 (19%)	24 (35%)
21–40	34 (68%)	124 (55%)		98 (59%)	60 (55%)		35 (52%)	123 (59%)		124 (59%)	34 (51%)
>40	6 (12%)	43 (19%)		33 (20%)	16 (15%)		17 (25%)	32 (15%)		43 (20%)	6 (9%)
Acute EVD clinical features⁴
Fever⁵	50 (100%)	205 (90%)	0·02³	161 (96%)	94 (85%)	0·001	62 (93%)	193 (92%)	0·87	194 (92%)	61 (91%)	0·72
Fatigue	49 (98%)	221 (98%)	1·00³	163 (98%)	107(98%)	1·00³	64 (96%)	206 (99%)	0·16³	206 (98%)	64 (97%)	0·63³
Headache	48 (96%)	206 (91%)	0·38³	157 (94%)	97 (89%)	0·13	60 (90%)	194 (93%)	0·39	196 (93%)	58 (88%)	0·15
Loss of appetite	47 (94%)	195 (86%)	0·13	149 (89%)	93 (85%)	0·34	61 (91%)	181 (87%)	0·33	183 (87%)	59 (89%)	0·62
Nausea or vomiting	40 (80%)	173 (77%)	0·60	134 (80%)	79 (72%)	0·13	51 (76%)	162 (78%)	0·81	163 (78%)	50 (76%)	0·75
Abdominal pain	34 (68%)	158 (70%)	0·79	114 (68%)	78 (72%)	0·56	49 (73%)	143 (68%)	0·47	148 (70%)	44 (67%)	0·56
Diarrhoea	41 (82%)	170 (75%)	0·31	130 (78%)	81 (74%)	0·56¹	50 (75%)	161 (77%)	0·69	160 (76%)	51(77%)	0·86
Blood in the stool	14 (28%)	61 (27%)	0·89	42 (25%)	33 (31%)	0·33	19 (29%)	56 (27%)	0·75	62 (30%)	13 (20%)	0·11
Myalgias or arthralgias	47 (94%)	203 (90%)	0·44³	155 (93%)	95 (87%)	0·12	65 (97%)	185 (89%)	0·04	193 (92%)	57 (86%)	0·18
Sore throat	14 (28%)	92 (41%)	0·09	114 (68%)	56 (51%)	0·005	14 (21%)	92 (44%)	0·0007	75 (36%)	31 (47%)	0·10
Hiccups	18 (26%)	86 (36%)	0·97	57 (34%)	43 (40%)	0·.37	32 (48%)	68 (33%)	0·02	78 (37%)	22 (33%)	0·57
Red eyes	37 (74%)	170 (76%)	0·82	134 (80%)	73 (68%)	0·02	57 (85%)	150 (72%)	0·03	165 (79%)	42 (65%)	0·02
Blurry vision	27 (54%)	136 (60%)	0·42	108 (65%)	55 (50%)	0·02	47 (70%)	116 (56%)	0·03	131 (62%)	32 (49%)	0·05
Bleeding gums	11 (22%)	68 (30%)	0·25	50 (30%)	29 (27%)	0·55	27 (40%)	52 (25%)	0·02	67 (32%)	12 (18%)	0·03
Miscarriage	2 (4%)	10 (4%)	1·00³	7 (4%)	5 (5%)	1·00³	3 (4%)	9 (4%)	1·00³	8 (4%)	4 (6%)	0·49³
Cycle threshold values at EVD diagnosis (N=190)⁶,⁷, Median (IQR)	22.4 (19.5–26.1)	26·8 (23·5–29·0)	<0·0001	25 (22·0–28·0)	27·7 (24·5–29·5)	<0·0001	26·5 (23·5–28·1)	26 (22·5–28·8)	0·96	26·5 (23·2–28·9)	24·1 (22·1–28·6)	0·15
Duration of acute EVD (N=190) ⁶,⁷, Median (IQR)	14 (9–19)	12 (9–17)	0·18⁵	13 (9–16)	12 (8–18)	0.54	13 (9–18)	13 (9–17)	0·87	12 (9–17)	14 (9–19)	0.15

Data are n (%) or median (IQR) unless otherwise stated. EVD=Ebola virus disease.

Symptoms began during ETU stay or after discharge; diagnoses includes uveitis or conjunctivitis

Symptoms began during ETU stay or after discharge

Fisher’s exact test

⁴

At anytime during acute EVD illness (before and within Ebola facility, including ETU), self-reported. Fever included history of fever within the 2 days prior to Ebola facility admission or temperature >38.0°C at the time of EVD case-investigation by the surveillance team. Acute EVD symptom data were missing in 32 of 4,155 responses (0.1%).

⁵

All patients with uveitis had a history of fever during acute EVD

⁶

A subset of patients had data on cycle-threshold and duration of acute EVD

⁷

Wilcoxon rank-sum 2-sided test was used because the distribution of the data were skewed